BASi has entered into a Preferred Provider Agreement with NJ-based Pharmasset, Inc., a clinical-stage pharmaceutical company specializing in novel drugs to treat viral infections, to provide preclinical services for pre-IND and post-IND activities. The agreement includes exclusive toxicology services as well as pharmaceutical analysis and bioanalytical services as needed. BASi president and chief executive officer Anthony S. Chilton, Ph.D., said, “The agreement between Pharmasset and BA...